ANIK — Anika Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 898437 ·
Last close
$12.85
Market Cap
$171.97M
52W High
$22.88
52W Low
$9.01
ADV30
119,981
Next earnings
2026-11-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 30,594,000 | 18,837,000 | -712,000 | -311,000 | 189,600,000 | 44,957,000 | 52,023,000 |
| Jun 2026 | 32,610,000 | 21,244,000 | 2,954,000 | 3,309,000 | 183,474,000 | 38,412,000 | 46,192,000 |
| Mar 2026 | 29,612,000 | 18,997,000 | -5,488,000 | -5,056,000 | 179,387,000 | 41,020,000 | 45,486,000 |
| Dec 2025 | 30,615,000 | 19,179,000 | 646,000 | 292,000 | 190,270,000 | 57,481,000 | 46,805,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$5,977,000
Investing CF
$-4,053,000
Financing CF
$-16,340,000
CapEx
$-5,415,000
Dividends Paid
—
Buybacks
$-15,057,000
EPS Diluted TTM
$-0.27
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$59,040,000
Inventory
$28,565,000
Receivables
$29,062,000
ST Investments
—
EBIT TTM
$-5,121,000
Pretax Income TTM
$-2,913,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$120,654,000
EBITDA
$3,040,000
Free Cash Flow
$3,062,375
Enterprise Value
$245,530,736
Total Cash
$38,412,000
Total Debt
$25,250,000
Shares Out
13,382,966
Trailing EPS
$-0.03
Book Value
$10.33
ROE
-2.2%
ROA
-0.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 112,819,000 | -11,051,000 | -10,880,000 | 190,270,000 | 46,805,000 | 143,465,000 | 11,188,000 |
| Dec 2024 | 119,907,000 | -5,101,000 | -56,385,000 | 202,740,000 | 48,751,000 | 153,989,000 | 5,403,000 |
| Dec 2023 | 120,792,000 | 844,000 | -82,667,000 | 270,632,000 | 58,367,000 | 212,265,000 | -1,788,000 |
| Dec 2022 | 113,827,000 | 3,670,000 | -14,859,000 | 349,128,000 | 63,565,000 | 285,563,000 | 4,409,000 |
TTM Snapshot
Revenues TTM
$120,654,000
NetIncome TTM
$-3,784,000
OpCashFlow TTM
—
Assets (Latest)
$183,474,000
Forward EPS
$0.95
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $20.00 · spot: $13.62 · call volume: 17 · put volume: 41
Expected Move to 2026-12-18:
±$2.20
(16.15%) —
implied range
$11.42 –
$15.82
· ATM straddle on $12.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ELMD | Electromed, Inc. | $189.06M | $23.13 | — |
| KRMD | KORU Medical Systems, Inc. | $151.38M | $3.49 | — |
| PDEX | PRO DEX INC | $198.18M | $61.93 | — |
| INGN | Inogen Inc | $147.82M | $5.68 | — |
| UTMD | UTAH MEDICAL PRODUCTS INC | $205.06M | $72.02 | — |
News headlines (Yahoo Finance, 1h cache)
Anika Therapeutics Inc (ANIK) Q3 2026 Earnings Call Highlights: Revenue Growth and Margin Gains ...
2026-11-06 21:17 · Yahoo
Anika Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-06 17:49 · Yahoo
Anika Therapeutics (ANIK) Q3 2026 Earnings Call Transcript
2026-11-06 17:28 · Yahoo
What Anika Therapeutics (ANIK) Said on Its Q3 Earnings Call
2026-11-06 16:14 · Yahoo
Anika Therapeutics (ANIK) Beats Q3 Earnings and Revenue Estimates
2026-11-06 12:25 · Yahoo
Anika: Q3 Earnings Snapshot
2026-11-06 12:22 · Yahoo
Anika Reports Third Quarter 2026 Financial Results
2026-11-06 12:05 · Yahoo
Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026
2026-10-22 20:01 · Yahoo
Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?
2026-09-25 12:40 · Yahoo
Regenxbio (RGNX) Reports Q3 Loss, Misses Revenue Estimates
2026-11-05 13:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.